Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This contribution presents data from the literature as well as our own results concerning the mechanisms of hepatic encephalopathy (HE). 1. Blood chemistry: In patients with
liver cirrhosis
, the plasma levels of ammonia, phenylalanine, tyrosine, phenolic acids, and octopamine correlated with the stages of HE. Methionine and free tryptophan concentrations were increased only in stages 2-4. Further, branched chain amino acids were below the normal range. Experimental findings in animals elucidated some mechanisms of these changes. 2. Effects of administered substances: With ammonia, methionine, methanethiol, tryptophan, phenolic substances, and fatty acids central nervous disturbances were observed. 3. Interactions: Anemia, methanethiol, and fatty acids favored ammonia toxicity. Alkalosis diminished cerebral symptoms. 4. Neurotransmitters: HE was accompanied by an enhanced turnover of serotonin and by increased amounts of false neurotransmitters (like octopamine) in the brain. 5. Oxydative brain metabolism: Disorders of cerebral oxygen and
glucose
utilization were mainly documented in cases of long term HE with EEG alterations. 6. Structural changes of the brain: Most of them are irreversible.
...
PMID:[Pathogenesis of hepatic encephalopathy (author's transl)]. 1 66
The breakdown of proinsulin in the pancreatic beta cell yields insulin and C-peptide which are secreted in equimolar amounts. Unlike insulin, C-peptide is not degraded significantly by the liver, so that its measurement should give a better assessment of insulin secretion than estimation of peripheral insulin levels alone; particularly in the presence of hepatic dysfunction. Plasma C-peptide and insulin response to an oral
glucose
load have therefore been assessed in 14 cirrhotic and 7 normal subjects. Cirrhotic patients were divided into hyperinsulinaemic and normoinsulinaemic groups based on fasting plasma-insulin concentrations. Fasting blood-blucose and plasma-C-peptide concentrations were the same in normal and cirrhotic subjects, suggesting that basal pancreatic insulin secretion was the same in all subjects. Thus the C-peptide/insulin ratio was significantly decreased in hyperinsulinaemic subjects (2-13 +/- 0-31, compared with 4-63 +/- 0-48 in controls). After oral
glucose
, the two groups of cirrhotic patients showed the same glucose intolerance. C-peptide concentrations were also the same but insulin concentrations were markedly increased in the hyperinsulinaemic group. It is suggested that pancreatic insulin secretion is not increased in
cirrhosis
and that the peripheral hyperinsulinism is due solely to decreased hepatic insulin degradation secondary to either spontaneous portal-systemic shunting or to parenchymal damage.
...
PMID:Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion? 6 54
For the purpose to study the citrate metabolism in liver diseases, blood citrate, blood
glucose
and serum non-esterified fatty acids (NEFA) in fasting state were measured in the subjects with chronic hepatitis and with
liver cirrhosis
. Citrate and
glucose
were measured by the enzymatic methods. NEFA was measured colorimetrically. Fasting blood citrate level was investigated in relation to the type and extent of these liver diseases. Results revealed the following: 1. Fasting blood citrate level rose with the severity of liver diseases, especially in decompensated
liver cirrhosis
. 2. No significant difference in fasting blood citrate level was found between the subjects with and without glucose intolerance. 3. Fasting blood citrate level had a closer correlation with serum NEFA level than with blood
glucose
level. From these results, it has been concluded that the increase in blood citrate level in liver diseases is due to the impaired uptake of citrate by the liver and the increased release of citrate from peripheral tissues.
...
PMID:Studies on citrate metabolism in liver injuries. 1. Fasting blood citrate level in chronic hepatitis and liver cirrhosis. 12 99
Development of
cirrhosis
of liver tissue did not influence the intensity of glycolysis, with
glucose
as a substrate, in supernatant fraction of liver homogenate in chronic intoxication with CCL4. In preparations of cirrhotic liver, as compared with liver from the intact animals, more distinct activation of glycolysis was caused by addition of ATP and NAD at the stage of 3-week intoxication and also by addition of hexokinase, glyceraldehydephosphate dehydrogenase and lactate dehydrogenase at the stage of distinct
cirrhosis
of liver (6 weeks of CCL4 intoxication). Km values for glucose-6-phosphate dehydrogenase increased over all the periods of intoxication.
...
PMID:[Change in the glycolytic and glucose-6-phosphate dehydrogenase activity in experimental cirrhosis of the liver]. 16 85
Glucagon was tested for its effect on plasma adenosine 3',5'-cyclic monophosphate (cyclic AMP), insulin, and
glucose
in healthy subjects and in patients with advanced
cirrhosis of the liver
. In the normal subjects, intravenous infusion of glucagon caused a significant increase in plasma cyclic AMP,
glucose
, and insulin. In advanced cirrhotics, plasma cyclic AMP,
glucose
, and insulin did not increase. Adenylate cyclase concentration was measured in liver tissue from end stage cirrhotic patients and from brain-dead organ donors whose cardiovascular function was maintained in a stable state. Basal and total adenylate cyclase concentration were not different in the two groups. Adenylate cyclase from the livers of advanced cirrhotics was, however, significantly less responsive to glucagon stimulation than was that from donor livers. Hepatocytes in advanced
cirrhosis
have abnormal metabolic behavior characterized by abnormal adenylate cyclase-cyclic AMP response to hormonal stimulation.
...
PMID:Cyclic AMP metabolism and adenylate cyclase concentration in patients with advanced hepatic cirrhosis. 21 45
A simple diagnostic strategy in the diagnosis of insulinoma in adult subjects is proposed based upon the literature and own experiences. It comprises measurement of plasma proinsulin, insulin and C-peptide as well as blood
glucose
after an overnight fast. When a low or normal proinsulin concentration is found, organic hyperinsulinaemia is very unlikely, while elevated proinsulin, after exclusion of uremia,
hepatic cirrhosis
, thyreotoxicosis and surreptitious administration of insulin or sulfonylurea drugs, strongly indicates this condition.
...
PMID:Strategy in the diagnosis of insulinoma. 22 87
The normal physiological role of glucagon is in controlling hepatic
glucose
output. Glucagon subserves the role of homeostasis by maintaining plasma
glucose
and of a stress hormone by producing hyperglycaemia. While control of glucagon release by circulating metabolites and also other hormones is clearly important, it seems likely that the nervous system exerts an over-riding influence. The parasympathetic nervous system maintains homeostasis and the sympathetic acts in stress. Glucagon levels are found to be high in
cirrhosis
and also after acute hepatic failure. It is likely that these changes in glucagon concentration are secondary to metabolic abnormalities. While some glucagon is cleared by the liver, a similar clearance is seen by many other tissues and it is not likely that the elevation of glucagon seen in liver failure is due solely to a gross deficiency of glucagon clearance. No liver abnormality is seen in the glucagonoma syndrome, where glucagon concentration are chronically high, or in patients who have had a total pancreatectomy, where plasma glucagon is undetectably low. It thus seems unlikely that liver mass is importantly controlled by glucagon.
...
PMID:Signals for glucagon secretion. 24 99
To investigate the development of diabetes mellitus in patients with thalassemia major, plasma
glucose
and immunoreactive insulin (IRI) levels following oral
glucose
and intravenous tolbutamide and
glucose
disappearance rates following intravenous insulin were measured in 10 patients before and during five years on a high transfusion program (HTP). Plasma immunoreactive glucagon (IRG) levels following oral
glucose
, intravenous insulin, and arginine were measured during the sixth year. Serial percutaneous liver biopsies were performed on seven patients. The oral
glucose
tolerance tests (OGAT) and mean peak IRI levels were normal in nine of 10 patients before HTP. After HTP was begun a progressive deterioration of OGTT occurred despite normal IRI levels. Following tolbutamide, the mean per cent fall in plasma
glucose
in the patients before HTP was significantly less than in controls (p less than 0.01) and similar to that of controls during five years of HTP in spite of higher than normal peak IRI levels. Of seven survivors after six years of HTP, three had normal OGTT and four had chemical diabetes; mean peak IRI levels were normal, but fasting IRG levels were significantly higher than in controls (p less than 0.05). In all seven patients, plasma IRG failed to increase following insulin-induced hypoglycemia and was significantly higher than in controls after arginine (p less than 0.01); after oral
glucose
, plasma IRG fell significantly below that of fasting only in the patients with chemical diabetes (p less than 0.03). Following intravenous insulin, the mean per cent fall in
glucose
before and during HTP was significantly less than in controls (p less than 0.01). Hemosiderosis and
cirrhosis
were present in all biopsied patients. Four patients died; two had chemical and two had nonketotic insulin-dependent diabetes. These data suggest that diabetes mellitus occurs frequently in patients with thalassemia on HTP and that insulin resistance and hyperglucagonemia, possibly due to
cirrhosis
, are important etiologic factors.
...
PMID:Carbohydrate metabolism and pancreatic islet-cell function in thalassemia major. 32 76
In order to explain the increase of total IRI frequently observed at basal status, and after
glucose
administration, in patients with chronic liver disease, plasma proinsulin-like component and insulin levels have been studied in fourteen patients with
liver cirrhosis
associated or not with clinical or subclinical diabetes mellitus. A significative increase of plasma insulin was observed at basal status and after a
glucose
load not only in subjects with clinical or subclinical diabetes but also in those patients without carbohydrate abnormalities. This increase is apparently not correlated to any clinical characteristic and is associated in fasting and after
glucose
load with increased proinsulin-like component levels especially in patients with clinical or subclinical diabetes.
...
PMID:Plasma proinsulin-like components and insulin in chronic liver disease. 32 82
To clarify further the etiology of the carbohydrate intolerance in idiopathic hemochromatosis, we investigated the
glucose
, insulin, C-peptide, and glucagon responses to arginine (0.5 g/kg) infused during 30 min in lean normal subjects; in insulin-requiring subjects with hemochromatosis, genetic diabetes, and total pancreatectomy; and in nondiabetic cirrhotic subjects without portosystemic shunting. Serum insulin, C-peptide, and glucagon responses (30K antibody) were determined by RIA, and
glucose
level was determined by a glucose oxidase technique. Hemochromatotic and genetic diabetic subjects had similar basal
glucose
(157 +/- 25 vs. 168 +/- 40 mg/dl) and C-peptide (0.73 +/- 0.42 vs. 0.65 +/- 0.22 ng/ml) values, with subnormal C-peptide peak responses to stimulation (1.05 +/- 0.38 and 1.40 +/- 0.83 vs. 3.95 +/- 0.4 ng/ml in normals; P less than 0.05). No glucagon or C-peptide response to arginine was seen in any pancreatectomized subject. Similar but excessive glucagon levels were present in hemochromatosis, diabetes, and
cirrhosis
under basal conditions (166 +/- 24, 232 +/- 111, and 263 +/- 116 vs. 76 +/- 15 pg/ml; P less than 0.05) and after arginine stimulation (782 +/- 80, 834 +/- 123, and 902 +/- 275 vs. 489 +/- 81 pg/ml; P less than 0.05) when compared with normals. The excessive glucagon levels found in hemochromatosis, diabetes mellitus, and
cirrhosis
contrast to the absent response in pancreatectomized subjects and indicate that generalized islet cell destruction is not the major factor in diabetic hemochromatotic subjects.
...
PMID:Pancreatic alpha-cell function in diabetic hemochromatotic subjects. 38 22
1
2
3
4
5
6
7
8
9
10
Next >>